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ABSTRAK
Penyakit Ginjal Kronik (PGK) merupakan masalah tidak hanya di Indonesia namun juga di dunia 
dengan angka insidensi yang cenderung meningkat. Sebagian besar pasien PGK meninggal akibat komplikasi 
kardiovaskular, dibandingkan akibat PGK nya sendiri. Faktor risiko tradisional saja tidak mampu menerangkan 
tingginya komplikasi kardiovaskular, namun faktor non-tradisional seperti stres oksidatif turut berperan dan 
menjadi target terapi. 
Stres oksidatif terjadi akibat ketidakseimbangan antara faktor pro oksidan yang dominan dibandingkan 
faktor antioksidan yang menurun pada penderita PGK yang menjalani hemodialisis (HD). Tindakan HD pun 
yang menggunakan membran selulosa dan semi selulosa turut berperan terhadap peningkatan oksidan serta 
mengaktifkan sistem komplemen, merangsang proses inflamasi yang berakhir dengan perburukan stress oksidatif.
Kata kunci: penyakit ginjal kronik, oksidan, stres oksidatif.
ABSTRACT
Chronic kidney disease (CKD) is a worldwide health problem with a high incidence not only in western 
countries but also in Indonesia as well. The majority of patients with CKD died due to cardiovascular disease 
than CKD progression itself. In addition to traditional risk factors, cardiovascular disease in CKD might also 
due to non-traditional risk factors. Oxidative stress, as non-traditional risk factors, is not only able to explain 
the high incidence of cardiovascular disease in CKD, but also become a new target in therapeutic intervention.
Oxidative stress in patients with CKD appears due to increased oxidant activity and decreased antioxidant 
system. Hemodialysis (HD) with the use of a cellulose and semi-cellulose membrane also contribute to increase 
oxidant that can activate the complement pathway. It stimulates inflammation that will further expand the 
production of oxidants and will ultimately increase oxidative stress.
Key words: chronic kidney disease, oxidant, oxidative stress.
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INTRODUCTION
Chronic kidney disease (CKD) is a worldwide 
health problem with a high incidence rate.1 This 
disease affects 10% of the adult population in the 
United States2 with a mortality rate of 20-50%.3 
In Indonesia, the incidence of CKD per million 
populations in 2002 was 14.5% and increased 
to 30.7% in 2006. Similarly, the prevalence per 
million populations increased from 10.2% in 
2002 to 23.4% in 2006.4 Chronic kidney disease 
will progressively develop into terminal renal 
failure. Kidney function decreases and leads to 
the emergence of a wide variety of complications 
including cardiovascular disease.2,5
Cardiovascular disease is the leading cause of 
death in the world, both in the general population 
and in patients with CKD. The majority of 
patients with CKD die due to cardiovascular 
disease than CKD progression itself.6,7 In 
addition to traditional risk factors, cardiovascular 
disease in CKD can also due to non-traditional 
risk factors. Oxidative stress, which is a non-
traditional risk factors, is not only able to explain 
the high incidence of cardiovascular disease 
in CKD, but also has become a new target in 
therapeutic intervention.8
Oxidative stress in patients with CKD appears 
due to increase oxidant activity and decrease 
antioxidant system. Increased oxidant activity, 
inflammation, and endothelial dysfunction are 
the triad foundation of atherosclerosis in patients 
with CKD8. Hypertension, uncontrolled high 
blood sugar and severe proteinuria in patients 
with CKD are also associated with oxidative 
stress and with the disease progression.9 
Hemodialysis (HD) with the use of a cellulose 
and semi-cellulose membrane also contribute to 
increase oxidant that can activate the complement 
pathway and stimulates inflammation that will 
further expand the production of oxidants and 
will ultimately increase oxidative stress.3,10,11 
This literature review will discuss the role of 
oxidative stress on the progression of CKD and 
antioxidants as therapeutic effects of oxidative 
stress.
CKD AND PROGRESSIVITY
Chronic kidney disease is a pathophysiological 
processes associated with renal function 
abnormalities and progressive reduction of 
glomerular filtration rate (GFR).3 Chronic kidney 
disease is defined as kidney damage or decreased 
kidney function (decreased GFR) for 3 months 
or more with or without regard to the presence 
or absence of the causes of kidney damage.12 
However, it should still be attempted to establish 
the diagnosis of CKD causes, degree of renal 
impairment, degree of decline in kidney function 
and the risk of further loss of kidney function, 
as well as the risk of cardiovascular disease.13
Table 1. Stages of chronic kidney disease5
Stages Description GFR  (mL/min/1.73 m2)
1 Kidney damage with 
normal or ↑ GFR
≥90
2 Kidney damage with 
normal or mild GFR ↓ 
60-89
3 Mild GFR ↓ 30-59
4 Severe GRF ↓ 15-29
5 Renal failure <15 or dialysis
Chronic kidney disease is defined as the presence of 
kidney damage and/or GFR <60mL/minutes/1.73 m2 
for ≥3 months. Kidney damage is defined as pathologic 
abnormalities or damage markers, including abnormalities 
in blood or urine tests or radiological examinations.
The pathophysiology of CKD involves two 
mechanisms. First, the initial mechanism of 
the specific underlying etiology (e.g., immune 
complex glomerulonephritis and inflammatory 
mediators to a specific type, or exposure to 
toxins in some renal tubules and interstitial 
disease). Second, a series of progressive 
mechanisms, involving hyperfiltration and 
hypertrophy of remaining viable nephrons due 
to a long-term decrease in renal mass. However, 
hyperfiltration and hypertrophy induced by 
vasoactive hormones, cytokines, growth factors, 
and increased activity of the intrarenal renin-
angiotensin system are short-term adaptation 
mechanisms that cause an increase intrarenal 
pressure and lead to the nephrosclerosis.3
Identification of the risk factors is necessary 
because the incidence of this disease is still high. 
CKD risk factors that cannot be modified include 
older age, family history of renal disease, reduced 
renal mass from childhood (in babies with low 
birth-weight), African ancestry, and low socio-
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economic status. Other risk factors that can be 
modified and facilitate the occurrence of CKD 
are also important to consider, such as diabetes, 
hypertension, autoimmune diseases, systemic 
infections, urinary tract infections, urinary tract 
stones, lower urinary tract obstruction, and drug 
toxicity.12
The major outcome of CKD is loss of 
kidney function leading to the emergence of 
complications of renal failure and cardiovascular 
disease. Progression of CKD is defined as 
a decline in kidney function, estimated by 
measuring GFR, creatinine clearance, or serum 
creatinine level5. There are two factors that can 
explain the progression of CKD, hemodynamic 
and non-hemodynamic factors.1 Six mechanisms 
that occur through hemodynamic factors are: 
1). Persistent glomerular injury produce local 
hypertension in capillary vessel, increasing 
GFR in every-single nephron and engenders 
protein leak into the tubular fluid. 2). Proteinuria 
increases angiotensin II production. 3). Cytokine 
is accumulated (cytokines bath) and able to 
induce the accumulation of mononuclear cells 
in the interstitial. 4). Interstitial neutrophils 
will be quickly replaced by macrophages 
and T-lymphocytes and induces nephrogenic 
immune response producing interstitial nephritis. 
5). Inflammation causes renal tubular cells 
move away from basal membrane and form new 
interstitial fibroblasts (epithelial-mesenchymal 
transitions). 6). Fibroblast lay down a collagenous 
matrix that disrupt adjecent capillaries and 
tubular nephrons, resulting a scar and ends up 
as fibrosis.3
Glomerular hypertension and hyperfiltration 
may cause damage in podocyte cells and 
endothelial cells, as well as mesangial cell 
proliferation.1 Remaining viable nephrons lose 
the ability to perform autoregulation, resulting 
in systemic hypertension, which will ultimately 
be more damaging to the glomerulus and worsen 
the CKD progression.3
There are many non-hemodynamic factors 
play a role in the progression of CKD. Some 
of these include angiotensin II, aldosterone, 
endothelin, acidosis, and oxidative stress. 
Angiotensin II will result in a reduction in 
glomerular size and selectivity, proteinuria, 
increased hydraulic pressure of the glomerulus 
and podocyte cell damage. Angiotensin II also 
increases the synthesis of extracellular matrix, 
activating cytokines, adhesion molecules, 
transcription factors and monocytes, causing 
inflammation. Aldosterone causes the proliferation 
of mesangial cells, apoptosis, hypertrophy, and 
podocyte cell damage which will exacerbate 
glomerular damage.1 Moreover aldosterone also 
acts as a mediator of angiotensin II which causes 
structural and functional damage to the blood 
vessels.14 Endothelin is a potent vasoconstrictor. 
In CKD the formation of endothelin will 
increase, and cause higher pressure on efferen 
blood vessels than afferent blood vessels, thus 
resulting in increased glomerular hydraulic 
pressure. Acidosis is often present in patients 
with CKD with a GFR below 20%. Acidosis 
activates the alternative complement pathway 
by increasing the formation of ammonia 
and induces the formation of endothelin and 
aldosterone production. Oxidative stress has 
contributed to worsening the progression of CKD 
through cardiovascular complications, including 
hypertension, inflammation, fibrosis and 
apoptosis, as well as damage to the glomerular 
filtration barrier.1
The assessment of CKD progression is 
often done by measuring GFR currently. This is 
because the rate of decline in GFR is relatively 
constant so that it can be used to estimate the 
time of renal failure occurrence. There are two 
approaches to estimate GFR decline. The first is 
the direct calculation of GFR by using formula. 
When GFR in the past and present is known, 
then the decline in GFR in the future could be 
predicted. The second approach is to look for 
the ascertain factors associatd with a “fast” 
or “slow” GFR decline. These factors include 
the type of kidney disease and the modifiable 
and non-modifiable factors. Diabetic kidney 
disease, glomerular disease, polycystic kidney 
disease, and renal disease after transplantation 
are types of kidney disease that accelerate GFR 
decline. Non-modifiable factors include older 
age, male gender, African-American race, lower 
baseline level of kidney function will accelerate 
the decline in GFR. Modifiable factors include 
higher level of proteinuria, lower serum albumin 
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levels, higher blood pressure, poor blood sugar 
control and smoking are associated with a faster 
GFR decline, thus worsening CKD progression.5
OXIDATIVE STRESS
Oxidative stress is a state of imbalance 
between excessive oxidant formation and lack 
of antioxidants as a defense mechanism.8,15 
Oxidant formation is physiologically important 
step in the process of tissue repair as a result 
of inflammation. This situation illustrates the 
self-defense mechanism against microorganisms 
and other foreign antigens. However, when 
this process occurs in chronic pathological 
conditions, it will have a detrimental effect and 
contribute to cell and tissue damage.7,8
Reactive oxygen species (ROS) is an 
oxidant produced by oxygen metabolite. ROS 
is radical because it has a single electron and 
an unpaired electron in the outer orbit. Radical 
oxygen metabolites include superoxide (•O2) 
and hydroxyl (•OH) while the non-radicals 
are hydrogen peroxide (H2O2), and singlet 
oxygen (1O2). They are all unstable substrates 
and highly reactive.17 Sources of ROS include 
the mitochondrial electron transport system 
(univalent reduction of molecular oxygen, 
NADH complex oxygenase), endothelial cells 
(xanthine oxidase reaction), inflammatory 
cells (myeloperoxidase, NADPH oxidase), 
catecholamine oxidation, and metabolism of 
arachidonic acid.16,17 One electron reduction of 
oxygen molecule may produce peroxide radicals 
(•O2-). By interfere of superoxide dismutase 
(SOD) enzyme, superoxide radical (•O2-), 
which is very unstable, will be converted into 
hydrogen peroxide (H2O2) immediately. Both 
superoxide radical (•O2-) and hydrogen peroxide 
(H2O2) are precursors of the formation other 
more powerful oxidants. Hydrogen peroxide 
(H2O2) is a strong oxidant that can interact with 
many organic substrates. Hydrogen peroxide 
(H2O2) generates hydroxyl radical (•OH) via the 
Fenton and Haber-Weiss reactions. Hydroxyl 
radical (•OH) has a very high reactivity, so they 
can immediately react with the target molecule 
formed around the place. Hydrogen peroxide 
(H2O2) and chlorine (Cl-) will be metabolized to 
hypochlorous acid (HOCl) by myeloperoxidase/
MPO.15,16 Superoxide radical (•O2-) will react 
with nitric oxide (NO) to form peroxynitrite 
(ONOO-). Peroxynitrite (ONOO-) will cause 
the endothelial nitric oxide synthetase (eNOS) 
become unpaired (uncoupled eNOS) that will 
form more superoxide radical (•O2-) and a 
cascade of ROS formation.17
The physiological formation of oxygen 
radicals will be detoxified by endogenous 
antioxidants. There are two types of antioxidants, 
enzymatic and non-enzymatic. Endogenous 
antioxidant generally present as enzymatic 
antioxidants, including SOD, catalase, and 
glutathione peroxidase containing selenium 
(GSH-Px). SOD will increase the speed of 
dismutase from superoxide (•O2-) to hydrogen 
peroxide (H2O2). Thus,  this enzyme is regarded 
as the first line of antioxidant defense. Exogenous 
antioxidants obtained from daily food intake is 
a type of non-enzymatic antioxidants, classified 
into hydrophilic (ascorbic acid/vitamin C, 
bilirubin, albumin, and flavonoids) and lipophilic 
(α-tocopherol/vitamin E, ubiquinol, and 
carotenoids). Vitamin C cleans the superoxide 
radical (•O2-) and hydroxyl radical (•OH), 
while vitamin E protects cell membranes from 
lipid oxidation1.5,16 Many antioxidants have 
synergistic relationship and mutually reinforcing. 
For example, vitamin C has the ability to recycle 
α-tocopherol. There are other types of exogenous 
antioxidants known as therapeutic agents 
previously, such as N-acetylsisteine (NAC), 
bardoxolone methyl11, and ACE-I/ARB.18
ROLE OF OXIDATIVE STRESS IN CKD 
PROGRESSIVENESS
Oxidative stress as part of non-hemodynamic 
factors plays a role in the progression of CKD, 
both directly through glomerular damage and 
renal ischemia or indirectly associated with 
inflammation, hypertension, and endothelial 
dysfunction1.9 Factors that cause an increase in 
oxidative stress in CKD include malnutrition, 
inflammation, increased phagocytic activity, 
increased oxidase activity, and a decrease in 
oxidative defense mechanisms.15
Oxidants produced by oxidative stress are 
a highly reactive component and has a very 
short half-life. Thus, the measurement is very 
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difficult. Oxidant is capable to oxidize wide 
variety components such as lipids, proteins, 
carbohydrates, and nucleic acids. Therefore, the 
oxidation product has a longer half-life, ranging 
from hours to weeks, so the product can be used 
as a marker of oxidative stress.8
There are many biological markers in 
patients with CKD, but the oxidation product 
of LDL (ox-LDL), advanced glycosylation 
end products (AGEs), and oxidized thiol 
components have contributed to the pathogenesis 
of cardiovascular disease and inflammation in 
CKD patients with uremic state. A study found 
that the levels of thiobarbituric acid-reactive 
substance (TBARS), which is a result of lipid 
oxidation, will increase in patients with CKD and 
is associated with the occurrence of endothelial 
dysfunction20. Whereas, the advanced oxidation 
protein products (AOPPs), which is a result of 
oxidation of the protein, will also increase in 
the uremic state, and the levels progressively 
rise in accordance with the decline in renal 
function1.5 Oxidants also interact with nucleic 
acids of a cell, leading to the inactivation of 
mitochondrial enzymes, and it will directly 
cause DNA damage, DNA repair enzymes and 
transcription factors, subsequently resulting in 
the death of these cells.19 Nucleic acid oxidation 
product, known 8-hydroxy-2’deoxyguanosine 
(8-OHdG) was found increase in patients with 
CKD. Therefore, AOPPs and 8-OHdG are also 
often used as markers of oxidative stress in 
patients with CKD.8
CKD patients are in a state of chronic 
inflammation and will activate inflammatory 
cells such as polymorphonuclear (PMNs) and 
monocytes.21 These inflammatory cells will 
increase the secretion of NADPH oxidase and 
MPO that will also enhance the formation of 
ROS oxidants.7,8 Leukocytes of CKD patients 
with uremia are known to be superoxide radical 
(•O2-) production source.15 Indoxyl sulphate (IS) 
is a form of the urea toxin that normally excreted 
through the kidneys. In patients with CKD, these 
organic anions will accumulate in the blood, 
aggravate inflammatory conditions and impair 
vascular endothelial function, thus worsening 
the progression of CKD.18
Superoxide radical (•O2-) inactivates NO, 
a paracrine which has an important role in the 
regulation of vascular tone. Physiologically, 
NO inhibits adhesion between leukocytes and 
vascular endothelial cells, proliferation of 
vascular smooth muscle cells (vascular smooth 
muscle cell/VSMC), and platelet aggregation. 
Thus, ensuring the surface of the blood vessels 
healthy and intact. If there is a decrease in NO 
level by any cause, there will be a decrease in the 
ability of blood vessels dilatation that contribute 
to hypertension.17,19
Nitric oxide is formed from semi-essential 
amino acid L-arginine with the aid of nitric 
oxide synthase (NOS) and tetrahydrobiopterin 
(BH4) as a cofactor. L-arginine is formed from 
citrulline, a result of amino acid metabolism 
in the digestive tract wall. Conversion of 
L-citrulline to L-arginine occurs in the kidney, 
so the amount of arginine in patients with CKD 
will reduce. Because of the lack of raw materials, 
the production of NO also reduced. In addition to 
inactivate NO, superoxide (•O2-) is also capable 
to react with NO itself. Their reaction produces 
a very strong oxidant, peroxynitrite (ONOO-). 
Peroxynitrite (ONOO-) is a nitrosating agent 
that has an ability to oxidize NOS and make it 
unstable. This unstable NOS will further augment 
superoxide (•O2-) production. Superoxide (•O2) 
Table 2. Markers of oxidative stress and antioxidant8
Markers of oxidative stress Antioxidants
Lipid peroxidation Enzymatic
 - Acrolein Superoxide 
dismutase
 - Malonyldialdehyde Catalase
 - 4-Hydroxynonenal Glutathione 
peroxidase
 - Thiobarbituric acid-reactive 
substance
Non enzymatic
 - F2 isoprostanes Glutathione
 - Advance lipid oxidation products Vitamin E
 - Oxidized LDL antibodies Vitamin C
Protein oxidation Ferritin
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is also able to oxidize tetrahydrobiopterine 
(BH4), causing NOS uncoupling, resulting in 
excess production of ROS.17,19
NOS activity inhibited by a NOS inhibitor. 
One of the examples is the asymmetric 
dimethylarginine (ADMA).22 ADMA works as 
a competitive inhibitor of endogenous NOS 
and inhibits NO formation that contributes 
to hypertension through vasoconstriction and 
inhibition of sodium excretion in the kidney. 
ADMA metabolic enzyme due to the increase 
in oxidative stress associated with angiotensin 
II. ADMA accumulation in CKD patients 
occurs via four mechanisms, increasing in 
methylation of proteins, increased protein 
turnover, decreased metabolic function of 
dimethylargininedimethylaminohydrolase 
(DDAH) as  the  impai rment  of  rena l 
excretory function.9 Patients with CKD 
will also have homocysteine accumulation 
(hyperhomocysteinemia/hHcy)  due to 
interference of protein metabolism. This 
situation will increase ROS, increase ADMA, 
and lowering NO. Thus, hHcy also becomes a 
risk factor for cardiovascular events in CKD that 
will worsen its progressiveness.23
An increase oxidative stress that plays a role 
in endothelial dysfunction also occurs through 
the accumulation of ADMA and reduction in NO 
bioavailability. Changes in vascular permeability 
will lead to the entry of LDL cholesterol into 
intimal layer. In patients with CKD whom 
in a state of uremia, oxidized LDL is easier 
happened than in normal person. Oxidized LDL 
(Ox-LDL) is a highly atherogenic molecule 
that initiates an inflammatory process in blood 
vessels. This process leads to the expression 
of leukocyte adhesion molecules and bound 
to inflammatory cells in the circulation. Then, 
these cells will migrate to the sub-endothelial 
cavity. Ox-LDL is going to be digested by 
monocytes which then turned into foam cells 
and form the fatty streak, the earliest structural 
changes that occur in atherosclerosis process. 
Along with its development, smooth muscle 
cells also migrate from the media to the intima 
layer, proliferate and produce extracellular 
matrix such as collagen, and form a fibrous 
cap. The ongoing inflammatory process cause 
the cap’s walls become thin and rupture 
easily. When the plaque ruptures, there will be 
thrombus formation, resulting acute myocardial 
infarction and stroke.7,15 A study by Alsegaff 
et al., describes the process of atherosclerosis 
that occurs in patients with CKD proved by the 
presence of carotid artery thickening associated 
with increased ADMA levels in plasma.24 This 
explains that oxidative stress worsen CKD 
progression through atherosclerosis process.7,15
Renin-angiotensin system plays an important 
role in regulating blood pressure. This system also 
has a role in the pathogenesis of inflammation 
and progression of CKD. T cells, natural killer 
cells, and monocytes are formed when many 
inflammatory processes have ability to express 
angiotensin II and AT1 receptor. Angiotensin II, 
through AT1 receptor, can stimulate oxidative 
stress through oxidative burst, has the ability 
to stimulate the activity of phagocytes and 
chemotaxis. So, in addition to the influence of 
inflammation on its formation, angiotensin II 
also causes inflammation and aggravates the 
process itself.21 In addition to work against 
NO, oxidants will also activate angiotensin II 
and aggravate vasoconstriction. Hypertension 
initially occurs in renal vasculature but then it 
will occur systemically. Angiotensin II can cause 
apoptosis of mesangial cells, damaging podocyte 
cells and tubulointerstitial cells, macrophage 
accumulation in the interstitial myofibroblast, 
and collagen deposition. It will eventually 
damage the whole kidney with the evidence of 
proteinuria.14
Proteinuria is a sign of glomerular damage 
and is associated with cardiovascular events 
and CKD progression.1 While proteinuria 
occurs, pro-inflammatory cytokines will be 
secreted. This will increase the production 
of ROS, aggravate fibrosis, and in the end 
worsening renal damage. Oxidative stress has a 
role in the occurrence of proteinuria by ADMA 
activity, leading to endothelial dysfunction, to 
the occurrence of cardiovascular disease, and 
ultimately contributes to the progression of CKD. 
Although the mechanism is not clearly known 
but one study explained that the decrease in 
ADMA levels in the blood is associated with a 
decrease in the degree of proteinuria.6,9
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Diabetes mellitus, in addition to be one of 
the traditional risk factors of cardiovascular 
disease emergence, apparently has correlation 
with oxidative stress in patients with CKD. The 
state of hyperglycemia would increase oxidative 
stress. Mitochondrial dysfunction, angiotensin 
II and the formation of AGEs as a product of 
oxidation of carbohydrates will increase the 
hyperglycemic state. AGEs increased the activity 
of NADPH oxidase and also increase oxidants 
formation. This causes deterioration of renal 
function through the glomerulosclerosis due 
to decreased podocyte cells, mesangial cells 
and transcription pathway activation. AGEs 
also cause endothelial dysfunction, stimulate 
monocyte influx and proliferation of cells that 
play a role in the atherosclerotic process. This can 
explain why hyperglycemic state may exacerbate 
CKD progression, either directly or indirectly, 
through vascular complications.2,8
In a state of oxidative stress the oxidation 
of blood cell lipid membranes may occur. This 
is proved by the increase in malondialdehyde 
(MDA) as a marker of lipid oxidation on 
erythrocyte surface of patients with CKD. 
Changes in the structure and function of 
erythrocytes will cause a decrease in erythrocyte 
membrane elasticity so it will shorten the lifespan 
of erythrocytes and increase the hemolysis 
probability. This is might explain the cause of 
anemia in patients with CKD in addition to the 
reduction of its formation1.5,25
CKD patients with regular HD also have 
increasing oxidative stress. Patients with HD 
may have cardiovascular events 3-50 times 
higher than those without undergoing HD.10 
Oxidative stress that occurs in HD is caused 
by the interaction between blood and dialysate 
membrane (bioincompatibility), bacterial 
products (endotoxins) in the dialysate which is 
able to cross the dialysis membrane and directly 
or indirectly stimulates the release of reactive 
species by neutrophils, loss of antioxidants 
during HD, and malnutrition related to poor 
intake of vitamins due to restrictions on fruits 
and vegetables to avoid hyperkalemia.8,11,15
ANTIOXIDANT SUPPLEMENT AND OXIDATIVE 
STRESS MANAGEMENT IN CKD
Antioxidants are now widely used as a 
therapy to reduce oxidative stress. There are 
two types of antioxidants, the endogenous 
and exogenous antioxidants.17 Exogenous 
antioxidants that obtained from outside the 
body are including vitamin C and vitamin E, 
N-acetylcystein (NAC), bardoxolone methyl, 
and ACEI/ARB.11,18
Vitamin E is a lipid-soluble antioxidant 
to regulate superoxide (•O2-) and hydrogen 
peroxide (H2O2) formation.
17 Although vitamin E 
is reported to decrease oxidative stress, there are 
some contrasting result studies. The Secondary 
Prevention with Antioxidants of Cardiovascular 
Disease in End Stage Renal Disease (SPACE) 
reported an association between a high intake of 
vitamin E with lower incidence of cardiovascular 
disease in CKD patients undergoing HD. 
However, Heart Outcomes Prevention Evaluation 
(HOPE), shows that vitamin E does not have the 
benefits of prevention and even increases the risk 
of cardiovascular disease.26,27 Vitamin C also has 
controversial results in its use as an antioxidant 
as vitamin C is metabolized into oxalate. Oxalate 
is insoluble. If it is in high amounts in the 
plasma, it will cause precipitation in soft tissues 
including kidney, so it will aggravate kidney 
damage, especially in patients with renal failure 
who have not been undergoing HD. Vitamin C 
supplementation is allowed no more than 60 mg/
day, while the studied dose considered successful 
in reducing oxidative stress is 250-1000 mg/
day.11,26
N-acetylcystein is an antioxidant often 
used as a mucolytic, acetaminophen poisoning 
antidote, and to avoid contrast induced 
nephropathy (CIN). N-acetylcystein will 
increase glutathione, an endogenous antioxidant 
with a help from cysteine.11 Several studies 
in experimental animals showed that NAC 
improve NO availability, reduce ADMA through 
increased DDAH activity, improves endothelial 
function, lowering albuminuria, so it can be 
used to prevent the risk of cardiovascular 
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disease. Research by Thaha et al., revealed that 
per-oral administration of NAC at a dose of 
2x600 mg in 3 months showed oxidative stress 
restoration through ADMA levels reduction and 
albuminuria in patients with non diabetic CKD 
stage I-IV.28 Another research by Thaha et al., 
explained intravenous administration of 5 g NAC 
decrease MDA level in CKD patients undergoing 
HD25 and with the same dose will reduce Hcy 
levels in patients with CKD associated with 
improvements in pulse pressure, which is 
expected to reduce the risk of cardiovascular 
events in CKD.23 Bardoxolone methyl has anti-
inflammatory effects that inhibit the production 
of oxidants and maintain kidney function and 
structure. Bardoxolone methyl at a dose of 25, 
75, or 150 mg once a day is said to be able to 
increase GFR in patients with CKD.18
ACE-I/ARB has an antioxidant effect by 
inhibiting angiotensin II action. Angiotensin 
II has the effect to increase NADPH oxidase 
and damage cell DNA that causes increased 
oxidative stress.18 In addition to lowering blood 
pressure, this drug will also lead to the formation 
of NADPH oxidase barriers, inhibiting lipid 
oxidation, inhibits DNA damage and reduces 
the occurrence of proteinuria, so it will reduce 
oxidative stress in patients with CKD.14,18
Oxidative stress in HD can be reduced by 
using interventions, reducing the activity of 
inflammatory cells and removing inflammatory 
mediators. Reduction of inflammatory cell 
activity achieved by using biocompatible 
synthetic dialysis membranes (e.g.,polysulfone) 
and using ultrapure dialysate. Inflammatory 
mediators can be removed by haemolipodialysis, 
using vitamin E coated dialysis membrane and 
the use of electrolyzed reduced water.29 Some 
studies investigate the use of HD-vitamin E 
coated dialysis membranes. Vitamin E coating on 
cellulose membranes can reduce oxidative stress 
and prevent damage of endothelial function due 
to HD. However, the use of vitamin E-coated 
membranes showed similar results to the level 
of a marker of oxidant when compared with 
synthetic membrane types. Therefore, it is not 
fully clear whether vitamin E coated membranes 
are more superior in reducing oxidative stress 
than synthetic membranes.15 In the end, it is still 
debatable when the right time to start a regular 
HD and whether HD implementation is able to 
repair or even aggravate oxidative stress that 
occurs in patients with terminal renal failure.8
CONCLUSION
The incidence of CKD is still high. This 
disease will progressively lead to end-stage 
renal disease. Many factors affect the speed of 
progression of CKD. One of them is oxidative 
stress. Oxidative stress occurs when there is 
an imbalance between oxidant formation and 
insufficient amount of antioxidants as a defense 
mechanism of the body. Oxidative stress 
causes cardiovascular disease easily occurs in 
patients with CKD through the mechanism of 
inflammation and endothelial dysfunction. In 
addition to directly damage the kidney, oxidative 
stress will be also associated with the excessive 
production of angiotensin II, hyperglycemia 
and proteinuria that may cause a worsening 
of CKD progression. Oxidants are capable to 
oxidize a wide variety of cell components such as 
carbohydrates, proteins, lipids, and nucleic acids, 
which in turn will further damage the kidneys. In 
patients with CKD, excess oxidant is not offset by 
sufficient antioxidants. At first, HD is proven to 
reduce oxidative stress as marked by a decrease 
in markers of oxidative stress. However, in the 
end HD itself will only lead to repeated oxidative 
stress through the bioincompatibility between 
dialysate membrane and blood, endotoxin in the 
dialysate, and the loss of antioxidant components 
during HD. Although still debated, the current 
administration of antioxidants is considered 
as one of the new therapeutic interventions in 
reducing oxidative stress. Antioxidants work 
through several mechanisms, such as damaging 
oxidants and inhibiting its formation either 
directly or indirectly, increase the activity of 
DDAH, thereby reducing ADMA and increase 
NO bioavailability NO, and inhibit the activity 
of the enzyme oxidase. All of these are expected 
to reduce oxidative stress and slower the 
progression of CKD.
Alisia Y. Putri                                                                                                              Acta Med Indones-Indones J Intern Med
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